Fluticasone furoate
- Generic Name
- Fluticasone furoate
- Brand Names
- Arnuity Ellipta, Avamys, Breo Ellipta, Flonase Sensimist, Trelegy Ellipta, Veramyst
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29F3O6S
- CAS Number
- 397864-44-7
- Unique Ingredient Identifier
- JS86977WNV
- Background
Fluticasone furoate is a synthetic glucocorticoid available as an inhaler and nasal spray for various inflammatory indications. Fluticasone furoate was first approved in 2007.
- Indication
Fluticasone furoate is indicated for once-daily maintenance (i.e. prophylactic) treatment of asthma in patients ≥5 years old. Fluticasone furoate is available in two combination medications - one in combination with vilanterol and one in combination with both vilanterol and umeclidinium- which are both indicated for the management of chronic obstructive pulmonary disease (COPD) and for the treatment of asthma in patients ≥18 years old for the vilanterol-umeclidinium-fluticasone product and ≥5 years old for the vilanterol-fluticasone product.
Fluticasone furoate is available over the counter as a nasal spray for the symptomatic treatment of hay fever and other upper respiratory allergies in patients ≥2 years old.
- Associated Conditions
- Asthma, Chronic Obstructive Pulmonary Disease (COPD), Perennial Allergy, Seasonal Allergies
- Associated Therapies
- -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
- First Posted Date
- 2015-07-20
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 60
- Registration Number
- NCT02502734
- Locations
- 🇩🇰
GSK Investigational Site, Randers, Denmark
A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2015-05-18
- Last Posted Date
- 2019-01-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 423
- Registration Number
- NCT02446418
- Locations
- 🇩🇪
GSK Investigational Site, Magdeburg, Germany
Study to Determine the Pharmacokinetics of GSK961081 and Fluticasone Furoate When Administered Alone or in Combination
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: GSK961081Drug: Fluticasone furoate
- First Posted Date
- 2014-02-17
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 48
- Registration Number
- NCT02064504
- Locations
- 🇦🇺
GSK Investigational Site, Randwick, New South Wales, Australia
RELOVAIR® Lung Deflation Study
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2012-09-25
- Last Posted Date
- 2016-10-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 45
- Registration Number
- NCT01691885
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Study FFR116364, a Placebo-controlled Study of GW685698X in Paediatric Subjects With Perennial Allergic Rhinitis
- Conditions
- Rhinitis, Allergic, Perennial
- Interventions
- Drug: PlaceboDrug: Fluticasone furoate
- First Posted Date
- 2012-06-28
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 261
- Registration Number
- NCT01630135
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
Study FFR116365, an Open-label Study of GW685698X in Paediatric Subjects With Perennial Allergic Rhinitis
- First Posted Date
- 2012-06-19
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 61
- Registration Number
- NCT01622231
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
A Dose-ranging Study of Fluticasone Furoate (FF)
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2012-03-26
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 597
- Registration Number
- NCT01563029
- Locations
- 🇺🇦
GSK Investigational Site, Zaporizhia, Ukraine
Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2011-10-17
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 26
- Registration Number
- NCT01453023
- Locations
- 🇺🇸
GSK Investigational Site, Huntington Beach, California, United States
Evaluating the Efficacy and Safety of Fluticasone Furoate in the Treatment of Asthma in Adults and Adolescents
- First Posted Date
- 2011-09-12
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 238
- Registration Number
- NCT01431950
- Locations
- 🇷🇺
GSK Investigational Site, Pyatigorsk, Russian Federation
Pharmacokinetics and PharmacoDynamics of GW685698 in Paedeatric Asthmatic Patients
- First Posted Date
- 2011-04-11
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 27
- Registration Number
- NCT01332292
- Locations
- 🇺🇸
GSK Investigational Site, Medford, Oregon, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.